» Articles » PMID: 31171025

Ablative Radiation Therapy for Locally Advanced Pancreatic Cancer: Techniques and Results

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2019 Jun 8
PMID 31171025
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Standard doses of conventionally fractionated radiation have had minimal to no impact on the survival duration of patients with locally advanced unresectable pancreatic cancer (LAPC). The use of low-dose stereotactic body radiation (SBRT) in 3- to 5-fractionshas thus far produced a modest improvement in median survival with minimal toxicity and shorter duration of treatment, but failed to produce a meaningful difference at 2 years and beyond. A much higher biologically effective dose (BED) is likely needed to achieve tumor ablation The challenge is the delivery of ablative doses near the very sensitive gastrointestinal tract. Advanced organ motion management, image guidance, and adaptive planning techniques enable delivery of ablative doses of radiation (> = 100Gy BED) when more protracted hypofractionated regimens or advanced image guidance and adaptive planning are used. This approach has resulted in encouraging improvements in survival in several studies. This review will summarize the evolution of the radiation technique over time from conventional to ablative and describe the practical aspects of delivering ablative doses near the GI tract using cone beam CT image (CBCT) guidance and online adaptive MRI guidance.

Citing Articles

Probing structural requirements for thiazole-based mimetics of sunitinib as potent VEGFR-2 inhibitors.

Abd Elhameed A, Ali A, Ghabbour H, Bayomi S, El-Gohary N RSC Med Chem. 2025; .

PMID: 39850549 PMC: 11753467. DOI: 10.1039/d4md00754a.


Interview with Prof. Dr. Jeffrey Drebin, President of the 2024 President Elect of the American Surgical Association.

Mimori K, Fujii T, Sho M, Endo I, Shirabe K, Kitagawa Y Ann Gastroenterol Surg. 2025; 9(1):24-31.

PMID: 39759979 PMC: 11693547. DOI: 10.1002/ags3.12882.


Feasibility of quantitative relaxometry for prostate target localization and response assessment in magnetic resonance-guided online adaptive stereotactic body radiotherapy.

Subashi E, LoCastro E, Burleson S, Apte A, Zelefsky M, Tyagi N Phys Imaging Radiat Oncol. 2024; 32():100678.

PMID: 39717186 PMC: 11665667. DOI: 10.1016/j.phro.2024.100678.


The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma.

Bryant J, Nakashima J, Khatri V, Sinnamon A, Denbo J, Hodul P J Clin Med. 2024; 13(22).

PMID: 39597944 PMC: 11594810. DOI: 10.3390/jcm13226800.


Daily Diagnostic Quality Computed Tomography-on-Rails (CTOR) Image Guidance for Abdominal Stereotactic Body Radiation Therapy (SBRT).

Martin-Paulpeter R, Jensen P, Perles L, Sawakuchi G, Das P, Koay E Cancers (Basel). 2024; 16(22).

PMID: 39594725 PMC: 11591933. DOI: 10.3390/cancers16223770.


References
1.
Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J . Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005; 76(1):48-53. DOI: 10.1016/j.radonc.2004.12.022. View

2.
Schellenberg D, Goodman K, Lee F, Chang S, Kuo T, Ford J . Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008; 72(3):678-86. DOI: 10.1016/j.ijrobp.2008.01.051. View

3.
Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O . Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of.... Ann Oncol. 2008; 19(9):1592-9. DOI: 10.1093/annonc/mdn281. View

4.
Iacobuzio-Donahue C, Fu B, Yachida S, Luo M, Abe H, Henderson C . DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27(11):1806-13. PMC: 2668706. DOI: 10.1200/JCO.2008.17.7188. View

5.
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View